Will the asthma revolution fostered by biologics also benefit adult ICU patients?
IL4Ralpha
IL5
T2 airway inflammation
asthma
severe exacerbation
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
26
11
2020
received:
25
09
2020
accepted:
29
11
2020
pubmed:
8
12
2020
medline:
10
8
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Asthma exacerbations are inflammatory events that rarely result in full hospitalization following an ER visit. Unfortunately, certain patients require prolonged support, including occasional external lung support through ECMO or ECCOR (with subsequent further exposure to other life-threatening issues), and some die. In parallel, biologics are revolutionizing severe asthma management, mostly in T2 high patients. We extensively reviewed the current unmet needs surrounding ICU-admitted asthma exacerbations, with a focus on currently available drugs and the underlying biological processes involved. We explored whether currently available T2-targeting drugs can reasonably be seen as potential players not only for relapse prevention but also as candidate drugs for a faster resolution of such episodes. The patient's perspective was also sought. About 30% of asthma exacerbations admitted to the ICU do not resolve within five days. Persistent severe airway obstruction despite massive doses of corticosteroids and maximal pharmacologically induced bronchodilation is the main cause of treatment failure. Previous ICU admission is the main risk factor for such episodes and may eventually be considered as a T2 surrogate marker. Fatal asthma cases are hallmarked by poorly steroid-sensitive T2-inflammation associated with severe mucus plugging. New, fast-acting T2-targeting biologics (already used for preventing asthma exacerbations) have the potential to circumvent steroid sensitivity pathways and decrease mucus plugging. This unmet need was confirmed by patients who reported highly negative, traumatizing experiences. There is room for improvement in the management of ICU-admitted severe asthma episodes. Clinical trials assessing how biologics might improve ICU outcomes are direly needed.
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Asthmatic Agents
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2395-2406Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992;268:3462-3464.
Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332-336. https://doi.org/10.1056/NEJM200008033430504
Bourdin A, Bjermer L, Brightling C, et al. ERS/EAACI Statement on severe exacerbations in asthma in adult: facts, priorities and key research questions. Eur Respir J. 2019;54(3). https://doi.org/10.1183/13993003.00900-2019
Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129:S34-S48. https://doi.org/10.1016/j.jaci.2011.12.983
Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. https://doi.org/10.1183/13993003.01046-2019
Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204. https://doi.org/10.2147/JAA.S176026
Bourdin A, Molinari N, Vachier I, et al. Mortality: a neglected outcome in OCS-treated severe asthma. Eur Respir J. 2017;50(5):1701486. https://doi.org/10.1183/13993003.01486-2017
Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax. 2012;67:754-756. https://doi.org/10.1136/thoraxjnl-2012-201869
Al-Dorzi HM, Al-Shammary HA, Al-Shareef SY, et al. Risk factors, management and outcomes of patients admitted with near fatal asthma to a tertiary care hospital in Riyadh. Ann Thorac Med. 2014;9:33-38. https://doi.org/10.4103/1817-1737.124441
Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J. 2005;12:265-270.
Gelb AF, Schein A, Nussbaum E, et al. Risk factors for near-fatal asthma. Chest. 2004;126:1138-1146. https://doi.org/10.1378/chest.126.4.1138
Turner M, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med. 1998;157:1804-1809. https://doi.org/10.1164/ajrccm.157.6.9708092
Abramson M, Bailey M, Couper F, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med. 2001;163:12-18. https://doi.org/10.1164/ajrccm.163.1.9910042
Beasley R. A historical perspective of the New Zealand asthma mortality epidemics. J Allergy Clin Immunol. 2006;117:225-228. https://doi.org/10.1016/j.jaci.2005.10.029
Pendergraft TB, Stanford RH, Beasley R, et al. Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations. Ann Allergy Asthma Immunol. 2004;93:29-35. https://doi.org/10.1016/S1081-1206(10)61444-5
Doshi V, Shenoy S, Ganesh A, et al. Profile of acute asthma exacerbation in drug users. Am J Ther. 2017;24:e39-e43. https://doi.org/10.1097/MJT.0000000000000118
Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448-2458. https://doi.org/10.1056/NEJMoa1703501
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197. https://doi.org/10.1056/NEJMoa1403291
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475-2485. https://doi.org/10.1056/NEJMoa1804093
Wu W, Bang S, Bleecker ER, et al. Multiview cluster analysis identifies variable corticosteroid response phenotypes in severe asthma. Am J Respir Crit Care Med. 2019;199(11):1358-1367. https://doi.org/10.1164/rccm.201808-1543OC
GSK NUCALA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf. Accessed 2 Apr 2020.
Astra Zeneca FASENRA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf. Accessed 2 Apr 2020.
SANOFI Dupixent. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Accessed 2 Apr 2020.
Novartis xolair_prescribing.pdf. https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed 2 Apr 2020.
TEVA CINQAERO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf. Accessed 2 Apr 2020
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486-2496. https://doi.org/10.1056/NEJMoa1804092
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115-2127. https://doi.org/10.1016/S0140-6736(16)31324-1
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. https://doi.org/10.1056/NEJMoa1403290
Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355-366. https://doi.org/10.1016/S2213-2600(15)00042-9
Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47:129-138. https://doi.org/10.1111/cea.12853
James AL, Elliot JG, Abramson MJ, Walters EH. Time to death, airway wall inflammation and remodelling in fatal asthma. Eur Respir J. 2005;26:429-434. https://doi.org/10.1183/09031936.05.00146404
de Magalhaes Simoes S, dos Santos MA, da Silva Oliveira M, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy. 2005;35:602-611. https://doi.org/10.1111/j.1365-2222.2005.02235.x
Venegas JG, Winkler T, Musch G, et al. Self-organized patchiness in asthma as a prelude to catastrophic shifts. Nature. 2005;434:777-782. https://doi.org/10.1038/nature03490
Wagner EM, Bleecker ER, Permutt S, Liu MC. Direct assessment of small airways reactivity in human subjects. Am J Respir Crit Care Med. 1998;157:447-452.
Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis. 1990;141:584-588. https://doi.org/10.1164/ajrccm/141.3.584
King GG, Carroll JD, Müller NL, et al. Heterogeneity of narrowing in normal and asthmatic airways measured by HRCT. Eur Respir J. 2004;24:211-218.
Ohrui T, Sekizawa K, Yanai M, et al. Partitioning of pulmonary responses to inhaled methacholine in subjects with asymptomatic asthma. Am Rev Respir Dis. 1992;146:1501-1505. https://doi.org/10.1164/ajrccm/146.6.1501
Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis. 1993;147:405-410. https://doi.org/10.1164/ajrccm/147.2.405
Green FHY, Williams DJ, James A, et al. Increased myoepithelial cells of bronchial submucosal glands in fatal asthma. Thorax. 2010;65:32-38. https://doi.org/10.1136/thx.2008.111435
James AL, Elliot JG, Jones RL, et al. Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care Med. 2012;185:1058-1064. https://doi.org/10.1164/rccm.201110-1849OC
Gelb AF, Yamamoto A, Mauad T, et al. Unsuspected mild emphysema in nonsmoking patients with chronic asthma with persistent airway obstruction. J Allergy Clin Immunol. 2014;133:263-265.e3. https://doi.org/10.1016/j.jaci.2013.09.045
Mauad T, Silva LFF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med. 2004;170:857-862. https://doi.org/10.1164/rccm.200403-305OC
James AL, Noble PB, Drew S-A, et al. Airway smooth muscle proliferation and inflammation in asthma. J Appl Physiol. 2018;125:1090-1096. https://doi.org/10.1152/japplphysiol.00342.2018
Kan M, Koziol-White C, Shumyatcher M, et al. Airway smooth muscle-specific transcriptomic signatures of glucocorticoid exposure. Am J Respir Cell Mol Biol. 2019;61:110-120. https://doi.org/10.1165/rcmb.2018-0385OC
Dolhnikoff M, da Silva LFF, de Araujo BB, et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol. 2009;123(5):1090-1097.e1. https://doi.org/10.1016/j.jaci.2009.02.032
Serrano-Pariente J, Plaza V. Near-fatal asthma: a heterogeneous clinical entity. Curr Opin Allergy Clin Immunol. 2017;17:28-35. https://doi.org/10.1097/ACI.0000000000000333
Hyzy RC, Travis WD, Hanna E, et al. Slow-onset asthma deaths have more eosinophils and health care utilization than rapid-onset deaths. Respir Med. 2008;102:1819-1826. https://doi.org/10.1016/j.rmed.2008.06.011
Rosner SR, Pascoe CD, Blankman E, et al. The actin regulator zyxin reinforces airway smooth muscle and accumulates in airways of fatal asthmatics. PLoS One. 2017;12:e0171728. https://doi.org/10.1371/journal.pone.0171728
de Medeiros Matsushita M, da Silva LFF, dos Santos MA, et al. Airway proteoglycans are differentially altered in fatal asthma. J Pathol. 2005;207:102-110. https://doi.org/10.1002/path.1818
Carroll N, Perry S, Karkhanis A, et al. The airway longitudinal elastic fiber network and mucosal folding in patients with asthma. Am J Respir Crit Care Med. 2000;161:244-248. https://doi.org/10.1164/ajrccm.161.1.9805005
Milanese M, Crimi E, Scordamaglia A, et al. On the functional consequences of bronchial basement membrane thickening. J Appl Physiol. 2001;91:1035-1040. https://doi.org/10.1152/jappl.2001.91.3.1035
McParland BE, Macklem PT, Paré PD. Airway wall remodeling: friend or foe? J Appl Physiol. 2003;95:426-434. https://doi.org/10.1152/japplphysiol.00159.2003
Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002;57:677-682.
Kuyper LM, Paré PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med. 2003;115:6-11. https://doi.org/10.1016/s0002-9343(03)00241-9
Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128:997-1009. https://doi.org/10.1172/JCI95693
Chen FH, Samson KT, Miura K, et al. Airway remodeling: a comparison between fatal and nonfatal asthma. J Asthma. 2004;41:631-638. https://doi.org/10.1081/jas-200026405
Benatar SR. Fatal asthma. N Engl J Med. 1986;314:423-429. https://doi.org/10.1056/NEJM198602133140706
Shijubo N, Itoh Y, Yamaguchi T, et al. Clara cell protein-positive epithelial cells are reduced in small airways of asthmatics. Am J Respir Crit Care Med. 1999;160:930-933. https://doi.org/10.1164/ajrccm.160.3.9803113
Ruiz García S, Deprez M, Lebrigand K, et al. Novel dynamics of human mucociliary differentiation revealed by single-cell RNA sequencing of nasal epithelial cultures. Development. 2019;146(20):dev177428. https://doi.org/10.1242/dev.177428
Rubin BK, Priftis KN, Schmidt HJ, Henke MO. Secretory hyperresponsiveness and pulmonary mucus hypersecretion. Chest 2014;146:496-507. https://doi.org/10.1378/chest.13-2609
Rossi RC, Anonni R, Ferreira DS, et al. Structural alterations and markers of endothelial activation in pulmonary and bronchial arteries in fatal asthma. Allergy Asthma Clin Immunol. 2019;15:50. https://doi.org/10.1186/s13223-019-0363-0
Mauad T, Nascimento FBPd, Dolhnikoff M, et al. Pulmonary interstitial emphysema in fatal asthma: case report and histopathological review. BMC Pulm Med. 2018;18:50. https://doi.org/10.1186/s12890-018-0615-7
Fraenkel DJ, Bardin PG, Sanderson G, et al. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med. 1995;151:879-886. https://doi.org/10.1164/ajrccm/151.3_Pt_1.879
Wang F, He XY, Baines KJ, et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J. 2011;38:567-574. https://doi.org/10.1183/09031936.00170110
Poznanski SM, Mukherjee M, Zhao N, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. Allergy. 2021;76(1):375-379. https://doi.org/10.1111/all.14514
Patel S, Shah NM, Malhotra AM, et al. Inflammatory and microbiological associations with near-fatal asthma requiring extracorporeal membrane oxygenation. ERJ Open Res. 2020;6(1):00267-2019. https://doi.org/10.1183/23120541.00267-2019
Corne JM, Marshall C, Smith S, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(1):831-834. https://doi.org/10.1016/S0140-6736(02)07953-9
Lamblin C, Gosset P, Tillie-leblond I, et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med. 1998;157:394-402. https://doi.org/10.1164/ajrccm.157.2.97-02099
Yii ACA, Tay T-R, Puah SH, et al. Blood eosinophil count correlates with severity of respiratory failure in life-threatening asthma and predicts risk of subsequent exacerbations. Clin Exp Allergy. 2019;49(12):1578-1586. https://doi.org/10.1111/cea.13465
Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849-858. https://doi.org/10.1016/S2213-2600(15)00367-7
Westerhof GA, Korevaar DA, Amelink M, et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J. 2015;46:688-696. https://doi.org/10.1183/09031936.00012415
Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med. 2015;3:824-825. https://doi.org/10.1016/S2213-2600(15)00419-1
Elliot JG, Noble PB, Mauad T, et al. Inflammation-dependent and independent airway remodelling in asthma. Respirology. 2018;23:1138-1145. https://doi.org/10.1111/resp.13360
Elliot JG, Jensen CM, Mutavdzic S, et al. Aggregations of lymphoid cells in the airways of nonsmokers, smokers, and subjects with asthma. Am J Respir Crit Care Med. 2004;169:712-718. https://doi.org/10.1164/rccm.200308-1167OC
Cagnoni EF, Ferreira DS, Ferraz da Silva LF, et al. Bronchopulmonary lymph nodes and large airway cell trafficking in patients with fatal asthma. J Allergy Clin Immunol. 2015;135(5):1352-1357.e9. https://doi.org/10.1016/j.jaci.2014.08.021
Elliot JG, Abramson MJ, Drummer OH, et al. Time to death and mast cell degranulation in fatal asthma. Respirology. 2009;14:808-813. https://doi.org/10.1111/j.1440-1843.2009.01551.x
Berger P, Girodet P-O, Begueret H, et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J. 2003;17:2139-2141. https://doi.org/10.1096/fj.03-0041fje
El-Shazly A, Berger P, Girodet P-O, et al. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J Immunol. 2006;176:1860-1868. https://doi.org/10.4049/jimmunol.176.3.1860
Girodet P-O, Ozier A, Trian T, et al. Mast cell adhesion to bronchial smooth muscle in asthma specifically depends on CD51 and CD44 variant 6. Allergy. 2010;65:1004-1012. https://doi.org/10.1111/j.1398-9995.2009.02308.x
Hollins F, Kaur D, Yang W, et al. Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6. J Immunol. 2008;181:2772-2780.
Tunon-de-Lara J-M, Berger P, Bégueret H. Mast cells in airway smooth muscle. N Engl J Med. 2002;347:1040-1041; author reply 1040-1041. https://doi.org/10.1056/NEJM200209263471318
Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346:1699-1705. https://doi.org/10.1056/NEJMoa012705
Fregonese L, Swan FJ, van Schadewijk A, et al. Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma. J Allergy Clin Immunol. 2005;115:1148-1154. https://doi.org/10.1016/j.jaci.2005.01.068
Sur S, Hunt LW, Crotty TB, Gleich GJ. Sudden-onset fatal asthma. Mayo Clin Proc. 1994;69:495-496. https://doi.org/10.1016/s0025-6196(12)61651-6
Burgel P-R, Lazarus SC, Tam D-W, et al. Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. J Immunol. 2001;167:5948-5954. https://doi.org/10.4049/jimmunol.167.10.5948
Persson EK, Verstraete K, Heyndrickx I, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019;364(6442):eaaw4295. https://doi.org/10.1126/science.aaw4295
Zhang X, Zhang LI, Wang G, et al. Clinical phenotypes of patients hospitalized for an asthma exacerbation: prognostic implications. J Allergy Clin Immunol Pract. 2020. https://doi.org/10.1016/j.jaip.2020.09.031
Serrano-Pariente J, Rodrigo G, Fiz JA, et al. Identification and characterization of near-fatal asthma phenotypes by cluster analysis. Allergy. 2015;70:1139-1147. https://doi.org/10.1111/all.12654
GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691-706. https://doi.org/10.1016/S2213-2600(17)30293-X
Salmeron S, Liard R, Elkharrat D, et al. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet. 2001;358:629-635.
Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis. 1992;146:76-81. https://doi.org/10.1164/ajrccm/146.1.76
Doshi V, Shenoy S, Ganesh A, et al. Near fatal asthma in an inner city population. Am J Ther. 2016;23:e1375-e1380. https://doi.org/10.1097/MJT.0000000000000152
Gonzalez Barcala FJ, Aboal Viñas J, Valdes Cuadrado L, et al. Trends in hospital admissions due to asthma in north-west Spain from 1995 to 2007. Allergol Immunopathol (Madr). 2010;38:254-258. https://doi.org/10.1016/j.aller.2009.11.008
Ponte EV, Souza-Machado A, Souza-Machado C, et al. Clinical characteristics and prognosis in near-fatal asthma patients in Salvador, Brazil. J Bras Pneumol. 2011;37:431-437. https://doi.org/10.1590/s1806-37132011000400004
Tanaka H, Nakatani E, Fukutomi Y, et al. Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study. Allergy. 2018;73:1110-1118. https://doi.org/10.1111/all.13374
Aubas C, Bourdin A, Aubas P, et al. Role of comorbid conditions in asthma hospitalizations in the south of France. Allergy. 2013;68:637-643. https://doi.org/10.1111/all.12137
Brenner B, Corbridge T, Kazzi A. Intubation and mechanical ventilation of the asthmatic patient in respiratory failure. J Allergy Clin Immunol. 2009;124:S19-S28. https://doi.org/10.1016/j.jaci.2009.05.008
Bond KR, Horsley CA, Williams AB. Non-invasive ventilation use in status asthmaticus: 16 years of experience in a tertiary intensive care. Emerg Med Australas. 2018;30:187-192. https://doi.org/10.1111/1742-6723.12876
Peters JI, Stupka JE, Singh H, et al. Status asthmaticus in the medical intensive care unit: a 30-year experience. Respir Med. 2012;106:344-348. https://doi.org/10.1016/j.rmed.2011.11.015
Yamauchi Y, Yasunaga H, Matsui H, et al. Comparison of in-hospital mortality in patients with COPD, asthma and asthma-COPD overlap exacerbations. Respirology. 2015;20:940-946. https://doi.org/10.1111/resp.12556
Kaur BP, Lahewala S, Arora S, et al. Asthma: Hospitalization Trends and Predictors of In-Hospital Mortality and Hospitalization Costs in the USA (2001-2010). Int Arch Allergy Immunol. 2015;168:71-78. https://doi.org/10.1159/000441687
Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33:14-20. https://doi.org/10.1016/j.ajem.2014.09.036
Tello K, Hoffmann A, Beutel B, et al. Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: a case-based discussion. Respir Med Case Rep. 2019;28:100927. https://doi.org/10.1016/j.rmcr.2019.100927
Shrimanker R, Pavord ID, Yancey S, et al. Exacerbations of severe asthma in patients treated with mepolizumab. Eur Respir J. 2018;52: https://doi.org/10.1183/13993003.01127-2018
Ramakrishnan S, Camp JR, Vijayakumar B, et al. The use of benralizumab in the treatment of near fatal asthma: a new approach. Am J Respir Crit Care Med. 2020;201(11):1441-1443. https://doi.org/10.1164/rccm.202001-0093LE
Pérez de Llano L, Blanco Cid N, Ortiz Piquer M, Dacal Rivas D. Compassionate use of a single dose of benralizumab in a near-fatal asthma exacerbation. J Investig Allergol Clin Immunol. 2020;31(3). https://doi.org/10.18176/jiaci.0609
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638-1650. https://doi.org/10.1016/S0140-6736(19)31881-1
Ferreira DS, Annoni R, Silva LFF, et al. Toll-like receptors 2, 3 and 4 and thymic stromal lymphopoietin expression in fatal asthma. Clin Exp Allergy. 2012;42:1459-1471. https://doi.org/10.1111/j.1365-2222.2012.04047.x
Groneberg DA, Eynott PR, Lim S, et al. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology. 2002;40:367-373. https://doi.org/10.1046/j.1365-2559.2002.01378.x
Shiang C, Mauad T, Senhorini A, et al. Pulmonary periarterial inflammation in fatal asthma. Clin Exp Allergy. 2009;39:1499-1507. https://doi.org/10.1111/j.1365-2222.2009.03281.x
Den Otter I, Silva LFF, Carvalho ALN, et al. High-affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. Clin Exp Allergy. 2010;40:1473-1481. https://doi.org/10.1111/j.1365-2222.2010.03576.x